Insulin Therapy in Diabetes Management

Introduction to Insulin Analogues

The American Diabetes Association recommends newer insulin analogs, including ultra-long-acting insulins, as the preferred choice for patients with type 1 diabetes and for type 2 diabetes patients requiring insulin who experience frequent hypoglycemia, due to their superior hypoglycemia reduction and equivalent glycemic control compared to human insulins 1, 2

In type 1 diabetes, treatment with analog insulins is associated with less hypoglycemia and weight gain as well as lower A1C compared with human insulins, according to the American Diabetes Association 1, 2
Rapid-acting analogs reduce HbA1c by an additional 0.15% compared to regular human insulin, as reported by the Annals of Internal Medicine 3
The critical advantage lies in hypoglycemia reduction: long-acting analogs significantly reduce severe hypoglycemia risk, with detemir showing the strongest effect, as stated by the Annals of Internal Medicine 3

The World Health Organization recommends human insulin as first-line therapy in resource-limited settings, but long-acting insulin analogs should be considered for adults with frequent severe hypoglycemia, as per the Annals of Internal Medicine 3, 2
For patients with type 2 diabetes who can afford them or have insurance coverage, long-acting analogs are preferred due to reduced hypoglycemia risk, particularly nocturnal hypoglycemia, according to Praxis Medical Insights 2

Total daily insulin requirements typically range from 0.4 to 1.0 units/kg/day, with approximately 50% as basal and 50% as prandial insulin, as recommended by the Diabetes Care journal 1
Start with 0.5 units/kg/day in metabolically stable patients, divided equally between basal and prandial components, as suggested by the Diabetes Care journal 1

Greatest caution is warranted for people at high risk of hypoglycemia, such as older patients and those with chronic kidney disease, according to Praxis Medical Insights 2
Higher insulin doses are required during puberty due to hormonal influences, as stated by Praxis Medical Insights 5

The World Health Organization strongly recommends human insulin for universal use in low-resource settings, with insulin analogs reserved for patients with frequent severe hypoglycemia, as reported by the Annals of Internal Medicine 3
In settings where cost is not prohibitive, the reduced hypoglycemia risk, improved quality of life, and greater dosing flexibility justify preferential use of insulin analogs, according to the Diabetes Care journal and Praxis Medical Insights 1, 2